Moderna announces clinical and program updates at 4th vaccines day

Next-generation, refrigerator-stable covid-19 vaccine candidate, mrna-1283, has dosed first participant in its phase 3 trial company expects to file for approval of its investigational rsv vaccine candidate, mrna-1345, this quarter company's first influenza candidate, mrna-1010, did not accrue sufficient cases at the interim efficacy analysis to declare early success in the phase 3 northern hemisphere efficacy trial and the independent dsmb recommended continuation of efficacy follow-up preliminary immunogenicity analysis from the northern hemisphere trial showed mrna-1010 demonstrated titers consistent with superiority against influenza a strains (h1n1, h3n2) and non-inferiority against influenza b strains (b/victoria, b/yamagata) versus the licensed comparator moderna announces new development candidates against lyme disease, the company's first bacterial vaccine, and norovirus, an enteric virus company establishes 2027 financial framework for the respiratory franchise cambridge, ma / accesswire / april 11, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced clinical and program updates demonstrating expansion and advancement of its mrna pipeline. the updates include advancements in the company's respiratory and latent virus portfolios, new vaccine candidates, and commercial and financial framework announcements for the respiratory vaccines business.
MRNA Ratings Summary
MRNA Quant Ranking